Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York.

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...